乌司他丁注射液在急危重症综合救治中应用的专家共识

2021-05-07 山东第一医科大学 山东第一医科大学(山东省医学科学院)学报

乌司他丁注射液是一种从人尿中提取纯化的天然水解酶抑制剂,能够有效抑制多种水解酶的活性和炎症因子的释放,阻断过度炎症反应。

中文标题:

乌司他丁注射液在急危重症综合救治中应用的专家共识

发布机构:

山东第一医科大学

发布日期:

2021-05-07

简要介绍:

乌司他丁注射液是一种从人尿中提取纯化的天然水解酶抑制剂,能够有效抑制多种水解酶的活性和炎症因子的释放,阻断过度炎症反应。自1998年在中国上市以来,被广泛应用于急危重症领域。但是药品说明书已远不能指导临床实践,超推荐剂量和超适应证使用乌司他丁的现象在当下已经十分普遍,超说明书用药增加了临床医生用药的障碍和风险。山东病理生理学会危重病医学专业委员会组织相关专家查阅国内外近年来对于乌司他丁注射液的相关研究,结合临床经验,对乌司他丁注射液临床应用相关问题进行讨论,形成乌司他丁注射液在急危重症综合救治中应用的专家共识,旨在为临床医生提供指导和建议。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=乌司他丁注射液在急危重症综合救治中应用的专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=49b641c0022e86d1, title=乌司他丁注射液在急危重症综合救治中应用的专家共识, enTitle=, guiderFrom=山东第一医科大学(山东省医学科学院)学报, authorId=0, author=, summary=乌司他丁注射液是一种从人尿中提取纯化的天然水解酶抑制剂,能够有效抑制多种水解酶的活性和炎症因子的释放,阻断过度炎症反应。, cover=https://img.medsci.cn/20211130/1638247801289_5579292.png, journalId=0, articlesId=null, associationId=2181, associationName=山东第一医科大学, associationIntro=山东第一医科大学, copyright=0, guiderPublishedTime=Fri May 07 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>乌司他丁注射液是一种从人尿中提取纯化的天然水解酶抑制剂,能够有效抑制多种水解酶的活性和炎症因子的释放,阻断过度炎症反应。自1998年在中国上市以来,被广泛应用于急危重症领域。但是药品说明书已远不能指导临床实践,超推荐剂量和超适应证使用乌司他丁的现象在当下已经十分普遍,超说明书用药增加了临床医生用药的障碍和风险。山东病理生理学会危重病医学专业委员会组织相关专家查阅国内外近年来对于乌司他丁注射液的相关研究,结合临床经验,对乌司他丁注射液临床应用相关问题进行讨论,形成乌司他丁注射液在急危重症综合救治中应用的专家共识,旨在为临床医生提供指导和建议。</p> <p>&nbsp;</p>, tagList=[TagDto(tagId=1683, tagName=乌司他丁), TagDto(tagId=17883, tagName=危重症)], categoryList=[CategoryDto(categoryId=38, categoryName=急重症, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1683, guiderKeyword=乌司他丁, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2309, appHits=140, showAppHits=0, pcHits=743, showPcHits=2169, likes=1, shares=15, comments=9, approvalStatus=1, publishedTime=Tue Nov 30 13:20:51 CST 2021, publishedTimeString=2021-05-07, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Tue Nov 30 12:54:24 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Thu Jan 04 20:12:13 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=乌司他丁注射液在急危重症综合救治中应用的专家共识.pdf)])
乌司他丁注射液在急危重症综合救治中应用的专家共识.pdf
下载请点击:
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2121521, encodeId=a1e6212152199, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bf48599470, createdName=ms3000001426429701, createdTime=Fri Mar 24 09:43:35 CST 2023, time=2023-03-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1221235, encodeId=9b741221235da, content=<a href='/topic/show?id=61152334003' target=_blank style='color:#2F92EE;'>#乌司他丁#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23340, encryptionId=61152334003, topicName=乌司他丁)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Fri May 20 17:17:14 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206334, encodeId=4435120633415, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Mar 27 12:02:08 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206330, encodeId=1c10120633013, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Mar 27 12:01:05 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189247, encodeId=00d1118924ead, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6eb4873931, createdName=290318491, createdTime=Sun Jan 30 06:17:02 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
    2023-03-24 ms3000001426429701 来自上海

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2121521, encodeId=a1e6212152199, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bf48599470, createdName=ms3000001426429701, createdTime=Fri Mar 24 09:43:35 CST 2023, time=2023-03-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1221235, encodeId=9b741221235da, content=<a href='/topic/show?id=61152334003' target=_blank style='color:#2F92EE;'>#乌司他丁#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23340, encryptionId=61152334003, topicName=乌司他丁)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Fri May 20 17:17:14 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206334, encodeId=4435120633415, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Mar 27 12:02:08 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206330, encodeId=1c10120633013, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Mar 27 12:01:05 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189247, encodeId=00d1118924ead, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6eb4873931, createdName=290318491, createdTime=Sun Jan 30 06:17:02 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2121521, encodeId=a1e6212152199, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bf48599470, createdName=ms3000001426429701, createdTime=Fri Mar 24 09:43:35 CST 2023, time=2023-03-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1221235, encodeId=9b741221235da, content=<a href='/topic/show?id=61152334003' target=_blank style='color:#2F92EE;'>#乌司他丁#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23340, encryptionId=61152334003, topicName=乌司他丁)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Fri May 20 17:17:14 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206334, encodeId=4435120633415, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Mar 27 12:02:08 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206330, encodeId=1c10120633013, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Mar 27 12:01:05 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189247, encodeId=00d1118924ead, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6eb4873931, createdName=290318491, createdTime=Sun Jan 30 06:17:02 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
    2022-03-27 120c570cm03暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2121521, encodeId=a1e6212152199, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bf48599470, createdName=ms3000001426429701, createdTime=Fri Mar 24 09:43:35 CST 2023, time=2023-03-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1221235, encodeId=9b741221235da, content=<a href='/topic/show?id=61152334003' target=_blank style='color:#2F92EE;'>#乌司他丁#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23340, encryptionId=61152334003, topicName=乌司他丁)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Fri May 20 17:17:14 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206334, encodeId=4435120633415, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Mar 27 12:02:08 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206330, encodeId=1c10120633013, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Mar 27 12:01:05 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189247, encodeId=00d1118924ead, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6eb4873931, createdName=290318491, createdTime=Sun Jan 30 06:17:02 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
    2022-03-27 120c570cm03暂无昵称

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2121521, encodeId=a1e6212152199, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bf48599470, createdName=ms3000001426429701, createdTime=Fri Mar 24 09:43:35 CST 2023, time=2023-03-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1221235, encodeId=9b741221235da, content=<a href='/topic/show?id=61152334003' target=_blank style='color:#2F92EE;'>#乌司他丁#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23340, encryptionId=61152334003, topicName=乌司他丁)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Fri May 20 17:17:14 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206334, encodeId=4435120633415, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Mar 27 12:02:08 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206330, encodeId=1c10120633013, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Mar 27 12:01:05 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189247, encodeId=00d1118924ead, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6eb4873931, createdName=290318491, createdTime=Sun Jan 30 06:17:02 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
    2022-01-30 290318491

    学习

    0

拓展阅读

加速康复外科中国专家共识暨路径管理指南(2018)

中华医学会外科学分会 · 2018-01-30

乌司他丁用于临床常见急危重症的专家共识

《乌司他丁用于临床常见急危重症的专家共识》专家组 · 2023-05-25